Cynosure Group LLC Has $360,000 Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Cynosure Group LLC lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 19.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,426 shares of the company’s stock after selling 1,850 shares during the period. Cynosure Group LLC’s holdings in Amphastar Pharmaceuticals were worth $360,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AMPH. TD Asset Management Inc raised its holdings in shares of Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after purchasing an additional 680,976 shares during the period. Epoch Investment Partners Inc. raised its stake in Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock worth $43,154,000 after buying an additional 280,390 shares during the period. American Century Companies Inc. boosted its holdings in Amphastar Pharmaceuticals by 19.7% in the second quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock worth $29,616,000 after acquiring an additional 121,764 shares in the last quarter. Millennium Management LLC boosted its holdings in Amphastar Pharmaceuticals by 84.6% in the second quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock worth $29,550,000 after acquiring an additional 338,653 shares in the last quarter. Finally, Boston Trust Walden Corp acquired a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $26,189,000. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $45.21 on Friday. The company has a fifty day moving average price of $47.91 and a 200-day moving average price of $44.51. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 15.07, a PEG ratio of 0.89 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92.

Analyst Upgrades and Downgrades

AMPH has been the topic of a number of recent research reports. Piper Sandler cut their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective for the company. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $60.33.

Insider Buying and Selling

In other news, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at $4,898,061.15. The trade was a 7.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Rong Zhou sold 6,893 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total transaction of $336,929.84. Following the completion of the transaction, the executive vice president now directly owns 118,388 shares in the company, valued at $5,786,805.44. This trade represents a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,533 shares of company stock worth $1,378,252. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.